Market Need OralCDx operates in cancer prevention within dentistry and ENT, presenting a clear opportunity to engage dental practices, primary care physicians, and specialists who screen for precancerous oral lesions. Leverage the device’s demonstrated accuracy and ADA Seal of Acceptance to position as a trusted screening tool that can drive early referrals.

Expansion Fit With a small internal team and a scalable, clinically validated test, there is potential to broaden adoption through partnerships with dental clinics, oral surgery centers, and gastroenterology/otolaryngology networks, enabling bundled solutions or co-marketing arrangements.

Tech & Ops Cloud-based infrastructure and modern tech stack indicate feasibility for integration with practice management systems, telehealth workflows, and digital patient education platforms, offering opportunities to create seamless ordering, results delivery, and compliance reporting experiences.

Growth Signals Revenue is in a mid-range, suggesting room for top-line expansion via channel partnerships, distributor networks, and regional sales teams, complemented by training programs to drive clinician adoption and patient awareness campaigns.

Strategic Partners Position CDx Diagnostics and OralCDx as leading prevention-focused brands to align with dental suppliers, medical device distributors, and preventive health initiatives, enabling co-branding, academic collaborations, and grant-funded awareness efforts.